PROTACs as Therapeutic Modalities for Drug Discovery in Castration-Resistant Prostate Cancer

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Castration-resistant prostate cancer (CRPC) poses clinical challenges due to resistance to standard androgen receptor (AR)-targeting therapies.
• Proteolysis targeting chimeras (PROTACs) represent a promising therapeutic strategy by enabling targeted protein degradation.
• Understanding AR signaling and resistance mechanisms is crucial for developing effective CRPC treatments.

Purpose of the Study:

• To review the advancements in PROTAC technology for CRPC treatment.
• To highlight PROTACs targeting AR and other CRPC-associated regulators.
• To discuss the potential of PROTACs in treating both CRPC and neuroendocrine prostate cancer (NEPC).

Main Methods:

• Literature review of PROTAC developments in prostate cancer.
• Analysis of strategic trends in AR PROTAC development, including targeting site selection and preclinical evaluation.
• Overview of clinical applications and ongoing research of AR degraders.

Main Results:

• PROTACs demonstrate significant potential in targeting AR and other key molecules in CRPC.
• Emerging PROTACs target chromatin modulators (BRD4, EZH2, SWI/SNF), transcription regulators (SMAD3), and kinases (CDK9, PIM1).
• Clinical applications of AR degraders are advancing, with ongoing development of selective AR degraders.

Conclusions:

• PROTACs are revolutionizing CRPC therapy by enabling targeted degradation of resistance-driving proteins.
• Targeting novel pathways beyond AR with PROTACs offers new therapeutic avenues for CRPC and NEPC.
• Continued research and clinical evaluation of PROTACs are essential for their successful integration into prostate cancer treatment paradigms.